Epigenetic aberrations and FLT3 mutations are common in ETP-ALL, which rationalizes the use of hypomethylating agents, BET inhibitors, and FLT3 inhibitors as reasonable novel therapies for ETP-ALL. Here, FLT3 is linked to acute lymphoblastic leukemia.